scholarly journals Protein tyrosine kinase 6 (PTK6; BRK); epidermal growth factor receptor (EGFR; ERBB1; HER1); v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ERBB2; HER2; Neu)

2008 ◽  
Vol 1 (29) ◽  
pp. 697-697
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tyrosine Kinase ◽  
Protein Tyrosine Kinase ◽  
Growth Factor Receptor ◽  
Protein Tyrosine ◽  
Viral Oncogene ◽  
Epidermal Growth ◽  
Viral Oncogene Homolog

Salicylanilides as Inhibitors of the Protein Tyrosine Kinase Epidermal Growth Factor Receptor.

ChemInform ◽  
2004 ◽  
Vol 35 (29) ◽  
Author(s):  
Christoph Liechti ◽  
Urs Sequin ◽  
Guido Bold ◽  
Pascal Furet ◽  
Thomas Meyer ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tyrosine Kinase ◽  
Protein Tyrosine Kinase ◽  
Growth Factor Receptor ◽  
Protein Tyrosine ◽  
Epidermal Growth

scholarly journals Companion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer

2013 ◽  
Vol 59 (10) ◽  
pp. 1447-1456 ◽  
Author(s):  
Michael J Duffy ◽  
John Crown
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tyrosine Kinase ◽  
Growth Factor Receptor ◽  
Severe Toxicity ◽  
Viral Oncogene ◽  
Anaplastic Lymphoma ◽  
Epidermal Growth ◽  
Viral Oncogene Homolog

BACKGROUND Companion biomarkers are biomarkers that are used in combination with specific therapies and that prospectively help predict likely response or severe toxicity. In this article we review the role of companion biomarkers in guiding treatment in patients with cancer. CONTENT In addition to the established companion biomarkers such as estrogen receptors and HER2 (human epidermal growth factor receptor 2) in breast cancer, several new companion biomarkers have become available in recent years. These include v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations for the selection of patients with advanced colorectal cancer who are unlikely to benefit from anti–epidermal growth factor receptor antibodies (cetuximab or panitumumab), epidermal growth factor receptor (EGFR) mutations for selecting patients with advanced non–small cell lung cancer (NSCLC) for treatment with tyrosine kinase inhibitors (gefitinib or erlotinib), v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations for selecting patients with advanced melanoma for treatment with anti-BRAF agents (vemurafenib and dabrafenib), and anaplastic lymphoma receptor tyrosine kinase (ALK) translocations for identifying patients with NSCLC likely to benefit from crizotinib. SUMMARY The availability of companion biomarkers should improve drug efficacy, decrease toxicity, and lead to a more individualized approach to cancer treatment.

Aggregation-induced activation of the epidermal growth factor receptor protein tyrosine kinase

Biochemistry ◽  
1993 ◽  
Vol 32 (34) ◽  
pp. 8742-8748 ◽  
Author(s):  
Moosa Mohammadi ◽  
Annemarie Honegger ◽  
Andrey Sorokin ◽  
Axel Ullrich ◽  
Joseph Schlessinger ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tyrosine Kinase ◽  
Protein Tyrosine Kinase ◽  
Growth Factor Receptor ◽  
Receptor Protein ◽  
Protein Tyrosine ◽  
Epidermal Growth ◽  
Receptor Protein Tyrosine Kinase
Sign in / Sign up

Export Citation Format

Share Document